Recent headlines from the sources AlphaScala monitors. AlphaScala analysis is published in the main market section.
Applied Materials carries a valuation that assumes the AI chip equipment cycle never slows. Three risks, cyclical, trade and competitive, threaten that setup. Alpha Score 68.
Beam Global's Q1 update shows backlog growth to $9M and Q2 revenue already exceeding Q1. The EV charging and drone infrastructure play gains demand visibility.
The S&P 500's 25.9% rally has compressed implied volatility, lowering future dividends for Nuveen's SPXX. The overwrite fund now faces a double risk: capped upside and vulnerable NAV.
SpaceX targets June 12 Nasdaq debut at $1.75T valuation, raising $75B. Lead underwriters GS, JPM, BAC see modest fee boost. Exchange win for Nasdaq.
The Nasdaq's 25.9% rally from the March 30 low has pushed the index into overbought territory, creating fragile positioning that risks a sharp retracement. Here's what to watch next.
Allarity Therapeutics reported Q1 EPS -$0.17, beating by $0.05. Cash of $29.8M sets a finite runway. The stock's next move depends on pipeline progress and the 10-Q cash burn details.
iQIYI reports Q1 2026 Monday before open. Consensus loss $0.03/sh, revenue $920M. Subscriber trend and AI cost savings decide the stock's direction.
Syntec Optics' Q1 revenue of $6.5M, down 8.5% YoY, and a GAAP loss of $0.02 per share raise cash burn concerns for the micro-cap optics maker. The 10-Q filing will be the next catalyst.
MiNK Therapeutics initiates 90-patient randomized Phase II ARDS trial; initial data in 2H 2026 creates a binary catalyst for INKT stock.
Expion360 Q1 GAAP EPS -$0.17 on revenue of $1.6M, down 22% Y/Y. Cash at $3.1M. The 22% revenue drop and cash burn create a binary outcome for XPON.
Intel’s $545B market cap prices in near-perfect foundry execution and CHIPS Act funding. Without marquee customers or margin proof, the 200% rally looks fragile.
Narrow market breadth and heavy options positioning leave the AI rally vulnerable to supply-chain shocks. Earnings season will test if AI demand translates into revenue.
Stock futures fell Friday after U.S.-China talks avoided chip restrictions. Traders also tracked Putin’s Beijing visit, Trump trades, and Walmart’s Flipkart.
The DAX fell 1.7% as inflation fears and stalled U.S.-China trade talks triggered profit-taking. Middle East tensions added a geopolitical risk bid.
Innovative Eyewear reported Q1 revenue of $773.6K, a 70% YoY increase, with cash at $5.68M and a GAAP loss of $0.37 per share. The cash runway now becomes the central question.
SpyGlass posted a $0.69 per-share loss; $251M cash funds operations through 2028. Phase 3 enrollment for its bimatoprost drug pad IOL is on track for 2027.
Chandan sees Nifty 27,000 fair value on accelerating profits and credit growth, but warns food inflation and monsoon are the next stress test for sentiment.
The record 38.6% margin signals the hub-and-powertrain shift is improving unit economics. 2026 revenue guidance holds at $40M–$50M. The next test comes with Q2 delivery data.
Dragonfly's Q2 sales guide of ~$13.2M, following a $3M+ trucking order, signals electrification demand. Readthrough for energy storage sector strengthens.
The slide deck for Faraday Future's Q1 2026 results is now public, giving investors a detailed look at the EV startup's cash position and production progress. The market will parse the deck for any changes to the FF 91 timeline.
Innventure posted $1.4M in Q1 revenue but disclosed $50M-plus in bookings, setting a $100M exit run-rate target for Accelsius by 2026. The gap defines the stock's next move.
AI Knowledge ARR climbed 26% in Q3. Higher U.S. RFP activity, new product launches, and a Q4 revenue view of $22.5M-$23.0M set the stage for the FY 2026 ramp.
The Q1 2026 presentation for Service Properties Trust (SVC) is now public. Investors will parse occupancy, RevPAR, and guidance for signs of a sustained hotel recovery.
RideNow's Q1 2026 call outlined an accretive acquisition strategy and a longer-term ~2x leverage goal. Refinancing progress and SEC update also in focus. Next: deal announcements.
Consensus calls for a $0.19 per-share loss on $15.49M in revenue. The report will test whether Surgepays can narrow losses and preserve cash as it scales its underbanked fintech platform.
Consensus calls for a loss of -$0.34 per share on $5.78M revenue. The May 14 after-close report tests whether Lifeward's beat streak and year-over-year growth can sustain the stock's recent range.
With cash at $1.2M and a quarterly burn of $5.2M, Stardust Power faces a financing decision that will determine dilution risk. The next capital raise filing is the critical catalyst.
Celcuity's $387M cash position funds operations through 2027. Rising operating cash use could shorten that runway. Alpha Score 35 signals weak momentum.
SGMT shares are up >30% in a month, giving the company a ~$450M market cap, but the stock remains >50% below its prior peak. The next denifanstat readout is the binary catalyst.
Higher rate expectations are widening the net interest margin outlook for First Hawaiian, a Hawaii-focused regional bank with an asset-sensitive balance sheet. The next CPI print will determine whether the rate tailwind persists.